Literature DB >> 18759204

[Acute pancreatitis: is there a need for surgery?].

A Kleespies1, W E Thasler, C Schäfer, G Meimarakis, M E Eichhorn, C J Bruns, K-W Jauch, N Zügel.   

Abstract

The treatment of acute pancreatitis is primarily non-surgical. An interdisciplinary approach as well as timely and aggressive intensive care has led to a significant improvement of the prognosis in severe necrotising pancreatitis. Early surgical procedures were associated with high morbidity and mortality and therefore were abandoned and replaced with forceful conservative treatment. However, there are still specific indications for surgery during the course of acute pancreatitis. These include cholecystectomy for biliary pancreatitis, surgical debridement of infected necrosis in septic patients and emergency operations for gastrointestinal perforations or haemorrhage. The following article focuses on surgical indications, optimal timing of surgery and competing surgical and non-surgical concepts like laparoscopic or endoscopic management. All mentioned procedures demand the cooperation of an experienced team of gastroenterologists, surgeons, radiologists and intensive care specialists, who are able to manage the potentially life-threatening complications of this disease. All patients with severe necrotising pancreatitis should be transferred to a specialised centre for interdisciplinary therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18759204     DOI: 10.1055/s-2008-1027467

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  2 in total

1.  [Acute pancreatitis].

Authors:  N Teich; S Leinung; S Jonas; J Mössner
Journal:  Chirurg       Date:  2009-03       Impact factor: 0.955

2.  [Video-assisted retroperitoneal debridement : Minimally invasive treatment and long-term results for necrotizing pancreatitis].

Authors:  R M Eickhoff; J Steinbusch; P Seppelt; A Kroh; K Junge; C D Klink; U P Neumann; M Binnebösel
Journal:  Chirurg       Date:  2017-09       Impact factor: 0.955

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.